Halozyme Therapeutics Inc. Watch

from 10-Q 11 pages Halozyme Therapeutics, Inc. Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 10-K 2 pages Halozyme Therapeutics, Inc. Severance Policy

from 10-Q 3 pages Material contract

from 10-Q 8 pages Halozyme Therapeutics, Inc. Director Stock Option Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 10-Q 10 pages Halozyme Therapeutics, Inc. Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 10-Q 9 pages Halozyme Therapeutics, Inc. Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 10-Q 11 pages Halozyme Therapeutics, Inc. Employee Stock Option Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 10-Q 20 pages Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan 1

from 10-Q 1 page Halozyme Therapeutics, Inc. Severance Policy

from 8-K 26 pages [ ]1 To: Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego, Ca 92121 From: [ ] Re: [Base]2[additional]3 Capped Call Transaction Ref. No: [ ]4 Date: [ ] Dear Ladies and Gentlemen

from 8-K 18 pages Security Agreement

from 10-Q 94 pages R E C I T a L S

from 10-K 10 pages Halozyme Therapeutics, Inc. Directors Deferred Equity Compensation Plan

from 10-K 5 pages Note: Execution of This Adoption Agreement Creates a Legal Liability of the Employer With Significant Tax Consequences to the Employer and Participants. Principal Life Insurance Company Disclaims All Liability for the Legal and Tax Consequences Which Result From the Elections Made by the Employer in This Adoption Agreement. Nothing Set Forth in This Agreement or Related Documents May Be Taken or Relied Upon as Legal, Tax, Investment, or Accounting Advice, Nor as Any Investment Recommendation. You Should Consult With Appropriate Counsel or Other Advisors on All Matters Pertaining to Legal, Tax, or Accounting Obligations and Requirements. Principal Life Insurance Company, Raleigh, Nc 27612 a Member of the Principal Financial Group® the Nonqualified Deferred Compensation Plan Adoption Agreement This Agreement Is the Adoption of the Nonqualified Deferred Compensation Plan ("Plan") by Halozyme Therapeutics, Inc. (The "Company") With an Ein of 88-0488686

from 8-K 16 pages Security Agreement

from 10-Q 11 pages Halozyme Therapeutics, Inc. Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 8-K 9 pages Halozyme Therapeutics, Inc. Director Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 8-K 13 pages Halozyme Therapeutics, Inc. Performance Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2011 Stock Plan

from 8-K 13 pages Halozyme Therapeutics, Inc. Restricted Stock Award Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan

from 8-K 11 pages Halozyme Therapeutics, Inc. Restricted Stock Units Agreement Under the Halozyme Therapeutics, Inc. 2021 Stock Plan